Stellar Pharmaceuticals Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Portugal
LONDON, ONTARIO–(Marketwire – 05/05/10) – Stellar Pharmaceuticals Inc. (Stellar) (OTC.BB: SLXCF – News ), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing a licensing agreement for the distribution and sale of one of its lead products, Uracyst (a sterile sodium chondroitin sulfate solution, 2%) for …

Read more on Marketwire via Yahoo! Finance